SPONSOR
Suzhou BlueHorse Therapeutics Co., Ltd.
Total Trials
2
Recruiting
2
Phases
EARLY_Phase 1, Phase 2
Suzhou BlueHorse Therapeutics Co., Ltd. is a clinical research sponsor with 2 registered studies on ClinicalTrials.gov, of which 2 are actively recruiting participants. Research covers conditions including Solid Cancer, Advanced Melanoma.
The trial portfolio spans EARLY_Phase 1, Phase 2 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Suzhou BlueHorse Therapeutics Co., Ltd.
How many clinical trials has Suzhou BlueHorse Therapeutics Co., Ltd. sponsored?
ClinicalMetric currently tracks 2 clinical trials sponsored by Suzhou BlueHorse Therapeutics Co., Ltd., of which 2 are actively recruiting participants. These trials cover conditions including Solid Cancer, Advanced Melanoma. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Suzhou BlueHorse Therapeutics Co., Ltd. research focus on?
Suzhou BlueHorse Therapeutics Co., Ltd. clinical trials span Solid Cancer, Advanced Melanoma. The research pipeline includes EARLY_Phase 1, Phase 2 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Suzhou BlueHorse Therapeutics Co., Ltd. clinical trial?
To participate in a Suzhou BlueHorse Therapeutics Co., Ltd. trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Suzhou BlueHorse Therapeutics Co., Ltd. trials with current recruitment status updated daily.
Clinical Trials by Suzhou BlueHorse Therapeutics Co., Ltd.
NCT06697665 EARLY_Phase 1
Recruiting
An Exploratory Clinical Study to Evaluate the Safety, Tolerability, Immune Response and Preliminary Efficacy of LM103 Injection in Combination With PD-1 in Patients With Advanced Solid Tumours
Solid Cancer
NCT07310784 Phase 2
Recruiting
A Phase II Trial of LM103 in Advanced Melanoma
Advanced Melanoma
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology